ERBB2 and triple-negative breast carcinoma: The results of the invasion assay against the BT-20 cell line (TNBC, triple-negative breast cancer) and T47D cell line (her2 negative cell line) showed that these antibodies represent potential anti-metastatic therapeutic candidates.